Live prices from 33 SA suppliers, from R340.00, compared side by side so you never overpay.
Copy the code — you'll paste it at checkout.
with our exclusive code
You're about to visit an external supplier
with our exclusive code
By clicking "Continue", you acknowledge that you understand and accept the above. Read our full disclosure.
Try removing a filter or two to widen the search.
Try removing a filter or two to widen the search.
More ways to compare Tesamorelin
Different views of the same live SA pricing, tuned for how you like to shop.
Compare another peptide
All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.
We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.
By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.
GHRH Analog | Visceral Fat Reduction
Tesamorelin is an FDA-approved synthetic GHRH analog designed for HIV-associated lipodystrophy treatment. It provides selective visceral fat targeting with 15-20% visceral fat reduction in clinical trials while preserving subcutaneous fat.
Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat.
HADGIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL
Histidine
Position 1
Alanine
Position 2
Aspartic Acid
Position 3
Glycine
Position 4
Isoleucine
Position 5
Phenylalanine
Position 6
Threonine
Position 7
Asparagine
Position 8
Serine
Position 9
Tyrosine
Position 10
Arginine
Position 11
Lysine
Position 12
Valine
Position 13
Leucine
Position 14
Glycine
Position 15
Glutamine
Position 16
Leucine
Position 17
Serine
Position 18
Alanine
Position 19
Arginine
Position 20
Lysine
Position 21
Leucine
Position 22
Leucine
Position 23
Glutamine
Position 24
Aspartic Acid
Position 25
Isoleucine
Position 26
Methionine
Position 27
Serine
Position 28
Arginine
Position 29
Glutamine
Position 30
Glutamine
Position 31
Glycine
Position 32
Glutamic Acid
Position 33
Serine
Position 34
Asparagine
Position 35
Glutamine
Position 36
Glutamic Acid
Position 37
Arginine
Position 38
Glycine
Position 39
Alanine
Position 40
Arginine
Position 41
Alanine
Position 42
Arginine
Position 43
Leucine
Position 44
FDA-approved indication showing 15-20% visceral fat reduction in clinical trials.
Unique mechanism that reduces dangerous visceral fat while sparing subcutaneous fat.
Maintained weight loss with continuous treatment over 52+ weeks in clinical studies.
12.3% reduction in triglyceride levels.
7.2% improvement in cholesterol markers.
37% liver fat reduction over 12 months.
Preserves lean muscle mass during fat loss.
26% increase in IGF-1 levels.
Subcutaneous injection to abdomen (avoid navel ±2 inches). Evening injection preferred for GH circadian rhythm alignment.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| HIV Lipodystrophy (FDA-approved) | 1.4mg | Once daily | SubQ |
| Visceral Fat Reduction | 2mg | Once daily | SubQ |
| Anti-aging/Body Composition | 1-2mg | 5-7x weekly | SubQ |
| NAFLD Treatment | 2mg | Once daily (12 months) | SubQ |
| Cognitive Enhancement | 1mg | Once daily (20 weeks) | SubQ |
Synergistic GH stimulation; monitor IGF-1 levels.
Combined use may elevate IGF-1 supraphysiologically.
Similar mechanism; risk of excessive effects at higher doses.
3.3-fold diabetes risk increase; monitor glucose closely.
May mitigate glucose intolerance associated with tesamorelin.
Decreases corticosteroid effectiveness.
Blocks GH release, negates tesamorelin effects.
Redundant; risk of acromegaly-like effects.
IGF-1 levels begin to rise, possible mild water retention or joint discomfort
Early metabolic changes; improved energy/sleep
Visible visceral fat reduction begins, waist circumference may decrease
Peak effects achieved with significant body composition improvements
Significant visceral adipose tissue reduction (-24 ± 41 cm² vs +2 ± 35 cm² placebo, p < 0.001) in HIV patients over 26 weeks.
69% achieved ≥8% VAT reduction vs 33% placebo at 26-52 weeks.
37% liver fat reduction over 12 months with fibrosis progression prevention.
Improved executive function and verbal memory in healthy elderly and mild cognitive impairment cohorts at 1mg daily.
Plain-English guides and study summaries from published literature.
Guides
8 min
Tesamorelin is a synthetic GHRH analogue best known for clinical research on visceral abdominal fat, especially in HIV-associated lipodystrophy. Here is what the evidence supports, and where claims should stay cautious.
Read article
Guides
7 min
Tesamorelin is an FDA-approved GHRH analogue with clinical evidence for HIV-associated lipodystrophy. Here is how it is discussed in visceral fat, GH and body composition research.
Read article
Guides
8 min
Tesamorelin is a synthetic GHRH analogue studied and used clinically for growth hormone stimulation, especially in relation to visceral abdominal fat and metabolic markers.
Read articleBe the first to know when prices drop on your favourite peptides
No spam. Unsubscribe anytime. We respect your privacy.